BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

Reuters11-22

<a href="https://laohu8.com/S/BRTX">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585122616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-22 08:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585122616","market":"nz","top_or_hot":-1,"title":"BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BRTX\">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-22 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BRTX\">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRTX","symbol_name":"BioRestorative Therapies, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251122:nNDL4XrrZs:1","article_id":"2585122616","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585122616","pubTimestamp":1763771364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells  and preclinical research on brown adipose-derived stem cells . The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRTX":"BioRestorative Therapies, Inc.","BK4139":"生物科技"},"translate_title":"BioRestorative Therapies Inc.在新的投资者介绍中公布了再生医学管道和商业计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRTX":0.9},"content_text":"BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    \n\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585122616","isCrawlerRequest":true}